SIC
NAGE

SJS Investment Consulting’s Niagen Bioscience NAGE Stock Holding History

SJS Investment Consulting’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125 Sell
39
-13
-25% -$53 ﹤0.01% 2565
2026
Q1 		$230 Buy
52
+7
+16% +$38 ﹤0.01% 1954
2025
Q4 		$287 Buy
+45
New +$313 ﹤0.01% 1705

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SJS Investment Consulting's NAGE Position: Q2 2026 in Review

SJS Investment Consulting reduced its Niagen Bioscience (NAGE) stake by 25% in Q2 2026, selling an estimated $53 and leaving 39 shares worth $125. The position accounts for ﹤0.01% of the portfolio, ranked #2565.

SJS Investment Consulting first reported a position in NAGE in Q4 2025 and has held it in 3 quarters since. The position peaked at $287 in Q4 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • SJS Investment Consulting held 39 shares of Niagen Bioscience worth $125 as of Q2 2026.
  • SJS Investment Consulting sold 13 Niagen Bioscience shares in Q2 2026, an estimated $53.
  • Niagen Bioscience made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2565 holding.
  • SJS Investment Consulting first reported a position in Niagen Bioscience in Q4 2025 and has held it in 3 quarters since.
  • SJS Investment Consulting's Niagen Bioscience position peaked at $287 in Q4 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.